Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial

Askanase, A. D., D’Cruz, D., Kalunian, K., Merrill, J. T., Navarra, S. V., Cahuzac, C., Cornelisse, P., Murphy, M. J., Strasser, D. S., Trokan, L., & Berkani, O. (2024). Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(24)00246-7

Authors:

Anca D Askanase

David D'Cruz

Kenneth Kalunian

Joan T Merrill

Sandra V Navarra

Clélia Cahuzac

Peter Cornelisse

Mark J Murphy

Daniel S Strasser

Luba Trokan

Ouali Berkani